Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short term Debt (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 13 years of Short term Debt data on record, last reported at $9.7 million in Q3 2025.

  • For Q3 2025, Short term Debt rose 5.13% year-over-year to $9.7 million; the TTM value through Sep 2025 reached $9.7 million, up 5.13%, while the annual FY2024 figure was $9.6 million, 4.24% up from the prior year.
  • Short term Debt reached $9.7 million in Q3 2025 per NWBO's latest filing, up from $9.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $341.9 million in Q1 2021 and bottomed at $1.0 million in Q1 2025.
  • Average Short term Debt over 5 years is $69.3 million, with a median of $9.2 million recorded in 2023.
  • Peak YoY movement for Short term Debt: soared 4323.22% in 2021, then plummeted 97.57% in 2022.
  • A 5-year view of Short term Debt shows it stood at $106.8 million in 2021, then fell by 24.56% to $80.6 million in 2022, then tumbled by 88.59% to $9.2 million in 2023, then increased by 4.24% to $9.6 million in 2024, then grew by 0.91% to $9.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $9.7 million in Q3 2025, $9.1 million in Q2 2025, and $1.0 million in Q1 2025.